CD64 enables TCR-dependent, MHC-independent CTL cytotoxicity of AML cells
Abstract
CD8+ T cell–mediated cytotoxicity classically occurs through engagement of an alpha-beta T cell receptor (TCRαβ) with a peptide–class I major histocompatibility complex (pMHC). However, it is also known that cytotoxic CD8+ T lymphocytes (CTLs) can kill tumor cells in a pMHC-independent manner. The relative physiologic contribution and biological significance of pMHC-independent CTL killing remain unclear, and a receptor shared between CTLs and natural killer (NK) cells is generally invoked as the mechanism by which this occurs. In this study, we used acute myeloid leukemia (AML) as a model to examine mechanisms of pMHC-independent cytotoxicity and found a paradoxical TCR-dependent, MHC-independent mechanism that requires CD64. Utilizing knockouts of potential AML ligands and CTL receptors, we demonstrate that pMHC-independent cytotoxicity is a potent mechanism of CTL-mediating killing of AML cells and is largely restricted to CD64-expressing cells through an IFNγ-regulated process. Notably, we found that pMHC-independent CTL killing is not due to activation of commonly implicated NK activating receptors but rather requires an activated TCRαβ/CD3 complex. Thus, we identify a CD64-dependent, pMHC-independent, TCR-dependent mode of CTL cytotoxicity that appears highly enriched for in AML.
Article Details
Journal Info
Proceedings of the National Academy of Sciences
National Academy of Sciences
Authors (11)
Kapil Saxena
Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Shao-Hsi Hung
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center
Esther Ryu
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center
Yulun Chiu
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center
Casey Bermack
Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Ke Pan
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center
Chunhua Shi
Oncology Research for Biologics and Immunotherapy Translation, The University of Texas MD Anderson Cancer Center
Priscilla Ortiz
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center
Shailbala Singh
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center
Marina Y. Konopleva
Department of Leukemia, The University of Texas MD Anderson Cancer Center
Cassian Yee